List of Excipients in Branded Drug VORAXAZE

Voraxaze Excipient Strategy and Commercial Opportunities

Last updated: September 6, 2026

Voraxaze, marketed as glucarpidase-vkjd, is a narrowly used recombinant enzyme for emergency treatment of toxic methotrexate concentrations in patients with delayed clearance or risk of methotrexate toxicity. Its commercial value depends less on broad prescription volume than on hospital availability, rapid procurement, formulation stability, and protection of a specialized manufacturing process.

The strongest excipient strategy is a low-complexity lyophilized formulation that preserves enzyme activity, supports rapid reconstitution, and limits administration risk. Commercial opportunities include improved storage, ready-to-use presentations, pediatric dosing formats, global supply expansion, and manufacturing technologies that reduce cost or improve batch consistency.

What is Voraxaze and how is it used?

Voraxaze is glucarpidase-vkjd, a recombinant carboxypeptidase enzyme that hydrolyzes methotrexate into inactive metabolites. The FDA approved Voraxaze in January 2012 under biologics license application 125327 for patients with toxic plasma methotrexate concentrations and delayed methotrexate elimination or risk of methotrexate toxicity.[1]

Product attribute	Voraxaze
Active ingredient	Glucarpidase-vkjd
Therapeutic class	Methotrexate rescue enzyme
Dosage form	Lyophilized powder for intravenous injection
Strength	1,000 units per single-dose vial
Recommended dose	50 units/kg intravenously over 5 minutes
FDA approval	January 2012
Regulatory pathway	Biologics license application
Primary use	Toxic methotrexate exposure with delayed clearance
Market structure	Hospital, oncology, and emergency-use product
Commercial model	Low-frequency, high-clinical-value intervention

Because glucarpidase can sharply reduce circulating methotrexate, leucovorin rescue and other supportive measures must be managed carefully. The product label warns that glucarpidase can interfere with methotrexate measurement depending on the assay used and that treatment should be reserved for clinically appropriate toxic exposure scenarios.[1]

What excipients are used in Voraxaze?

Voraxaze is supplied as a sterile, white to off-white lyophilized powder for reconstitution before intravenous administration. The formulation uses a limited excipient system intended to protect a protein enzyme during freeze-drying and storage.

The U.S. prescribing information identifies inactive formulation components that include lactose, tromethamine, and a zinc salt.[1] The zinc component is technically relevant because glucarpidase is a zinc-dependent enzyme. Tromethamine provides buffering capacity, while lactose can act as a stabilizing bulking agent and protect the protein structure during lyophilization.

Excipient function	Voraxaze formulation rationale
Zinc salt	Supports the metalloenzyme structure and catalytic activity
Tromethamine	Provides pH control during manufacture and reconstitution
Lactose	Provides cake structure and protein stabilization during drying
Lyophilization	Improves long-term stability of the recombinant enzyme
Single-dose vial	Reduces preservative requirements and contamination risk

The formulation is commercially conservative. It does not rely on a complex surfactant system, high excipient loading, or a multidose container. That approach reduces compatibility issues and simplifies hospital preparation.

What formulation risks affect glucarpidase?

The key technical risks are loss of catalytic activity, aggregation, adsorption to container surfaces, changes in reconstitution time, and sensitivity to temperature excursions. Enzyme potency is more important than total protein concentration because the clinical objective is rapid methotrexate hydrolysis.

Potential development variables include:

• pH and buffer concentration
• Zinc-ion availability
• Residual moisture after lyophilization
• Reconstitution volume and mixing time
• Container closure compatibility
• Particulate formation
• Protein aggregation
• Freeze-thaw sensitivity before final drying
• Stability during shipment to hospitals

A formulation change that improves convenience but lowers enzymatic activity would have limited commercial value. Any reformulation would require comparative analytical characterization, forced-degradation work, potency testing, and likely regulatory bridging.

What excipient strategy is commercially attractive for Voraxaze?

The most attractive strategy is to preserve the current low-excipient architecture while improving usability and supply reliability. A new formulation should solve a specific hospital problem: faster preparation, lower wastage, longer shelf life, easier pediatric dosing, or broader geographic distribution.

1. Ready-to-use liquid presentation

A ready-to-use liquid could eliminate reconstitution steps and reduce preparation errors. The principal development challenge would be maintaining glucarpidase activity in an aqueous environment over the proposed shelf life.

A liquid product would require optimization of:

• Buffer strength
• Zinc concentration
• Protein concentration
• Osmolality
• Container material
• Silicone-oil exposure
• Subvisible particles
• Refrigerated or room-temperature storage

The business case is strongest for emergency departments and oncology centers that need immediate access but may not use the product frequently. The weakness is supply-chain complexity and the possibility of a shorter shelf life.

2. Improved lyophilized formulation

An improved lyophilized formulation is likely to have a lower regulatory and technical risk than a liquid product. Opportunities include reduced reconstitution time, higher resistance to temperature excursions, improved cake appearance, and extended shelf life.

Potential excipient candidates include alternative sugars, polyols, amino acids, and surfactants. Each option has tradeoffs. Sugars can improve protein stabilization but may affect cake structure and moisture behavior. Polyols can improve physical stability but may alter tonicity. Surfactants can reduce interfacial stress but may introduce oxidation, leachables, or additional control requirements.

The preferred approach is a minimal-change formulation with a strong comparability package rather than a broad excipient redesign.

3. Pediatric and weight-based presentations

The standard dose is weight-based. A 50-unit/kg dose can require partial-vial calculations in smaller patients, creating waste and preparation complexity. Smaller-strength vials, dual-strength packaging, or a presentation optimized for pediatric oncology could improve dose accuracy.

A pediatric presentation would have commercial value if it reduces:

• Partial-vial waste
• Pharmacy preparation time
• Dose-calculation errors
• Delays in emergency treatment
• Inventory burden for smaller hospitals

The commercial opportunity is constrained by the small patient population and the need to avoid creating multiple low-volume stock-keeping units.

4. Room-temperature stability

Voraxaze is an emergency rescue therapy. Hospital buyers value products that can be stored in emergency pharmacies, oncology units, or regional stockpiles without strict cold-chain dependence.

A room-temperature-stable formulation could expand use in:

• Community hospitals
• Rural oncology centers
• Emergency transport systems
• International markets with unreliable refrigeration
• Government and hospital preparedness inventories

Temperature-stability claims would require real-time and accelerated stability data, container-closure studies, transport validation, and regulatory review in each market.

When does Voraxaze lose exclusivity?

Voraxaze’s seven-year U.S. orphan-drug exclusivity period ran from the January 2012 approval and generally ended in January 2019, subject to the statutory scope of the orphan designation and any regulatory complications.[1][2]

Orphan exclusivity does not prevent all forms of competition. It blocks FDA approval of the same drug for the same orphan indication during the protected period, subject to statutory exceptions. It does not replace patent protection, and it does not prevent all alternative formulations or products with different regulatory positioning.

Exclusivity category	Voraxaze status
FDA orphan-drug exclusivity	Seven-year period beginning in 2012; generally expired in 2019
New chemical entity exclusivity	Not the principal protection for this biologic enzyme
Patent exclusivity	Must be assessed separately from FDA exclusivity
Biologic reference-product exclusivity	BLA-based reference-product protection applies under the biologic framework
Pediatric exclusivity	No general six-month extension should be assumed without a specific FDA grant
Market exclusivity today	Primarily dependent on manufacturing, supply, clinical know-how, and any surviving patent rights

What is the Orange Book status of Voraxaze?

Voraxaze is licensed as a biologic under a BLA rather than approved as a conventional small-molecule drug under an NDA. Patent listings for biologics are generally handled through the Purple Book framework rather than the Orange Book.[3]

As a result:

• Voraxaze should not be analyzed as an ordinary Orange Book small-molecule product.
• A conventional Paragraph IV certification is not the primary biosimilar challenge mechanism.
• A future biosimilar applicant would generally use the Public Health Service Act section 351(k) pathway.
• Patent disputes could arise through the biologics patent dance and related federal litigation rather than the standard Hatch-Waxman sequence.

A company evaluating competitive entry must review the Purple Book, FDA biologics records, issued U.S. patents, patent assignments, regulatory exclusivity, and manufacturing constraints.

How strong is the patent estate for Voraxaze?

The commercial patent position is likely less important than for a conventional small-molecule medicine because glucarpidase is an established recombinant enzyme with a limited clinical use case. The relevant protection categories may include:

• Recombinant glucarpidase sequences
• Host-cell and expression systems
• Protein purification
• Formulation and stabilization
• Lyophilization processes
• Methotrexate detoxification methods
• Dosing and timing protocols
• Analytical potency assays
• Manufacturing controls and release specifications

Method-of-use patents may have value where they claim specific toxic methotrexate concentrations, patient subgroups, timing windows, or combined use with leucovorin. Their practical strength depends on claim scope, written-description support, prosecution history, and whether physicians or hospitals directly practice the claimed method.

Manufacturing know-how may provide stronger practical barriers than narrow formulation patents. A competitor must produce an enzyme with consistent catalytic activity, acceptable impurity levels, low aggregation, and validated sterility. That process-development burden can deter entry even after formal regulatory exclusivity has expired.

Are Paragraph IV challenges or biosimilar threats active?

A conventional Paragraph IV challenge is not the expected pathway for Voraxaze because the product is a BLA biologic. The more relevant threat is a future 351(k) biosimilar or interchangeable product.

No broad biosimilar competition should be assumed. Glucarpidase creates several development hurdles:

1. The product is an enzyme rather than a simple chemical molecule.
2. Activity depends on structural attributes and metal-ion functionality.
3. The clinical market is small and episodic.
4. Comparative clinical development may be difficult to finance.
5. Hospitals require rapid access and confidence in emergency dosing.
6. Manufacturing consistency is essential.
7. The reference product has limited demand outside specialized oncology care.

A biosimilar entrant could still pursue the market if it combines lower manufacturing cost with hospital contracting, regional supply, or a differentiated presentation. The principal commercial risk would likely emerge first through institutional tendering and specialty-distributor substitution, not through mass retail generic erosion.

What patent litigation affects Voraxaze?

Publicly material litigation should be reviewed across three categories: patent disputes involving glucarpidase composition or use, biologics patent litigation involving the reference product, and commercial disputes involving distribution or supply. The existence of an FDA approval does not establish that a product has a broad enforceable patent estate.

For commercial diligence, the highest-value litigation questions are:

• Whether any issued patent claims the marketed formulation
• Whether patent terms extend beyond regulatory exclusivity
• Whether claims cover the approved dosing method
• Whether a future biosimilar would trigger a section 351(l) exchange
• Whether manufacturing patents are enforceable against an independently developed process
• Whether settlement agreements restrict launch timing or supply arrangements

Without a current patent-family and court-docket review, no specific active patent, settlement, or litigation date should be treated as established.

Which companies could challenge Voraxaze?

The most credible challengers would be companies with capabilities in recombinant enzymes, orphan biologics, hospital injectables, or oncology supportive care. Potential entrant profiles include:

Challenger profile	Likely competitive route
Biosimilar developer	351(k) glucarpidase product
Specialty biologics company	Regional or indication-focused product
Injectable manufacturer	Lower-cost sterile presentation
Enzyme platform company	Improved stability or liquid formulation
Hospital-supply company	Contract manufacturing and institutional tenders
Global oncology company	Expanded geographic distribution and bundled procurement

The commercial barrier is not merely obtaining approval. A challenger must maintain emergency inventory, satisfy hospital pharmacy requirements, support toxicology consultation, and ensure reliable cold-chain or shelf-stable distribution.

What are the commercial opportunities for Voraxaze?

Voraxaze has five main commercial opportunities.

Hospital availability contracts

Hospitals may pay for reliable inventory even when annual utilization is low. Regional stocking programs, emergency pharmacy agreements, and guaranteed-replenishment contracts can reduce treatment delays.

International expansion

Markets with high-volume methotrexate use, pediatric oncology programs, or centralized cancer centers are the most logical targets. Regulatory approval, pricing, and reimbursement will determine whether smaller markets can support direct commercialization.

Improved logistics

A longer shelf life, room-temperature stability, or smaller vial format could increase adoption without changing the active ingredient. These improvements may produce more commercial value than a new therapeutic indication.

Manufacturing partnerships

A licensing or contract-manufacturing deal could monetize process expertise while expanding supply. The most valuable partner would have validated sterile biologics capacity and access to oncology hospital channels.

Rescue-product portfolio expansion

Voraxaze could anchor a specialty emergency portfolio covering methotrexate toxicity, chemotherapy extravasation, and other oncology rescue interventions. Bundled sales could improve hospital contracting, although the clinical and regulatory identities of each product would remain separate.

How does Voraxaze compare with conventional methotrexate rescue?

Voraxaze is not a replacement for leucovorin. It removes methotrexate from circulation through enzymatic cleavage, while leucovorin supports folate metabolism and reduces intracellular toxicity. Standard supportive care, hydration, urine alkalinization, methotrexate monitoring, and renal support remain clinically relevant.

Attribute	Voraxaze	Leucovorin rescue
Function	Enzymatic methotrexate degradation	Folate rescue
Use case	Toxic concentration with delayed clearance	Standard rescue after high-dose methotrexate
Administration	Single intravenous dose based on weight	Repeated dosing based on methotrexate levels
Commercial model	Emergency specialty biologic	High-volume generic and branded drug
Competitive risk	Biosimilar and formulation entry	Broad generic competition
Main value driver	Rapid methotrexate reduction	Prevention or mitigation of cellular toxicity

Key Takeaways

• Voraxaze is a specialized recombinant enzyme with a low-volume but high-clinical-value market.
• Its formulation relies on lyophilization and a limited excipient system that includes lactose, tromethamine, and a zinc salt.
• The best formulation opportunity is a minimal-change product with improved stability, faster reconstitution, or easier pediatric dosing.
• U.S. orphan-drug exclusivity generally expired in 2019.
• Voraxaze is a BLA biologic, so Purple Book and 351(k) analysis are more relevant than conventional Orange Book and Paragraph IV analysis.
• Biosimilar risk is currently constrained by small market size, enzyme complexity, manufacturing requirements, and emergency-use logistics.
• Manufacturing know-how, hospital availability, and supply reliability may provide stronger practical protection than formulation patents alone.
• Commercial expansion is most attractive through hospital stocking programs, international distribution, improved storage, and specialized manufacturing partnerships.

FAQs

Can Voraxaze be reformulated as a prefilled syringe?

A prefilled syringe could improve emergency administration but would require demonstrating long-term enzyme stability, container compatibility, sterility, extractables and leachables control, and dose accuracy. A liquid prefilled product would likely face greater development risk than an improved lyophilized vial.

Does zinc in the formulation create a patent opportunity?

Zinc may be important to glucarpidase activity, but the commercial value of a zinc-containing formulation claim depends on novelty, claim breadth, enablement, and prior art. A narrow excipient claim would need to provide a measurable stability or potency advantage.

Could a generic manufacturer make Voraxaze?

A conventional generic pathway is generally not the expected route because Voraxaze is a biologic licensed under a BLA. A competing company would more likely pursue a biosimilar or a separately regulated biologic product.

Would room-temperature stability materially expand Voraxaze sales?

Yes, particularly in hospitals that cannot justify refrigerated emergency inventory. The value would be greatest in regional cancer centers, rural hospitals, international markets, and emergency stockpile systems.

Is Voraxaze vulnerable to substitution with leucovorin?

Leucovorin does not perform the same pharmacologic function as glucarpidase. It is a rescue treatment used in methotrexate management, while glucarpidase rapidly degrades circulating methotrexate. Clinical substitution depends on the toxicity scenario and methotrexate clearance status.

References

1. U.S. Food and Drug Administration. (2024). Voraxaze (glucarpidase-vkjd) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity. FDA.

3. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.